GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice.

Area of Science:

• Immunology
• Clinical Chemistry
• Neurology

Background:

• Glutamic acid decarboxylase 65 (GAD65) antibodies are biomarkers for autoimmune diabetes and neurological disorders.
• Radioimmunoprecipitation assay (RIA) is a traditional method for GAD65 antibody detection, but enzyme-linked immunosorbent assay (ELISA) offers potential advantages.

Purpose of the Study:

• To validate GAD65-ELISA for type 1 diabetes and autoimmune neurological diagnoses.
• To correlate ELISA results with established RIA methods.
• To define the clinical utility and limitations of GAD65-ELISA.

Main Methods:

• Serum and cerebrospinal fluid (CSF) samples were analyzed using both ELISA and RIA.
• ELISA performance was assessed for analytical criteria including precision, accuracy, sensitivity, and specificity.
• Dilution protocols were validated to extend the reportable range of the ELISA.

Main Results:

• GAD65-ELISA demonstrated analytical validity and clinical equivalence to RIA for autoimmune diabetes detection.
• Established neurological cut-offs for ELISA were 10,000 IU/mL for serum and 100 IU/mL for CSF.
• ELISA showed higher clinical specificity (97.5% serum, 100% CSF) compared to RIA.

Conclusions:

• GAD65-ELISA is a sensitive and highly specific method for diagnosing autoimmune diabetes and neurological conditions.
• A serum cut-off of 10,000 IU/mL requires clinical context for interpretation.
• Dilution of samples exceeding 250 IU/mL is crucial for accurate neurological interpretation.